HemophiliaNCT06261593
Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy
A study testing Blood flow restriction in people with Hemophilia, run by Investigación en Hemofilia y Fisioterapia at 1 site in Spain.
Trial summary
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy. Objective. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men only
- Conditions the study is for
- Hemophilia
- What is being tested?
- Blood flow restriction
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 31 participants
- Where
- 1 siteSpain
- Study dates
- 6 Apr 2024to 20 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with hemophilia A and B
- People with a medical diagnosis of hemophilic ankle arthropathy
- Patients over 18 years of age
- Paceinets in prophylactic or on-demand treatment regimen with FVIII/FIX concentrates.
- Failure to sign the informed consent document
Who cannot join
- Patients with neurological or cognitive alterations that prevent understanding of the questionnaires
- Amputee patients, epileptics or patients with severe vision problems
- Patients who are receiving physiotherapy treatment at the time of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of a Physiotherapy Intervention Through Blood Flow Restriction in Improving Muscle Strength in Patients With Hemophilic Ankle Arthropathy: Multicenter Randomized Clinical Study
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy.
Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, stability, joint pain, joint status and the perception of quality of life in patients with hemophilic ankle arthropathy.
Read more
Study design. Randomized, multicenter, single-blind clinical study. Method. 32 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 4 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (The Single Leg Stance Test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks.
Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy.
- Conditions
- Hemophilia
- Being tested
- Blood flow restriction
- Keywords
- Hemophilia, Blood flow restriction, Physiotherapy, Muscular strength, Muscle activation, Range of Motion, Chronic pain, Stability
- Medical subject headings
- Hemophilia A, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood flow restrictionOther
The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | The intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy.
The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes. Receives: Other: Blood flow restriction |
| Control group | No intervention | The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline hemarthrosis after treatment and at 4 weeks
A self-registration will be used to evaluate the frequency of bleeding, and thus the safety of the technique. This selfregistration will be given to each patient at the beginning of the study and they must fill in the number of hemarthrosis and their main characteristics: date, origin (traumatic or spontaneous) and location (knee, ankle or elbow). The selfregistration will be delivered to the evaluator in each of the study evaluations (post-treatment and follow-up).
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Secondary outcomes (5)
Change from baseline pressure pain threshold after treatment and at 4 weeks
With a pressure algometer (model Wagner FPN100) the investigators will measure the pressure pain threshold, at the joint level and at a distance (in another part of the body). This device measures in Newton / cm2 the pressure at which the subject perceives pain under pressure. A pressure will be made on the chosen point, which the investigators will increase at an approximate speed of 50kPa / s until the patient warns us that the sensation begins to be painful.
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline muscle strength after treatment and at 4 weeks
With a pressure dynamometer (microFET®2 Digital Handheld model) the investigators will measure the strength of the tibialis and gastrocnemius. This device measures in Newton the force that the patient exerts in the requested muscular action. The higher the value, the greater the muscle strength. The investigators will carry out the measurements bilaterally. The patient will be asked 4 maximum isometric contractions of 5 seconds, with a rest of 30 seconds between them, against the dynamometer located in the hand of the evaluator
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline electrical activity of the muscles after treatment and at 4 weeks
Using surface electromyography (model SHIMMMER2, Shimmer, Ireland), the investigators will evaluate the electrical activity of the musculature and its level of activation. The placement of the electrodes will be marked on the standing subjects, and they will be placed following the European recommendations for the use of the SEMG. A bipolar SEMG system will be used with circular electrodes 10 mm in diameter, 20 mm apart, placed longitudinally, in the direction of the fibers of the studied muscle, and with a remote reference electrode.
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline joint status after treatment and at 4 weeks
With the Hemophilia Joint Health Score scale, specific for its use in patients with hemophilia, the joint status of patients with hemophilic arthropathy will be evaluated. It evaluates 8 items: inflammation and duration of this, pain, muscle atrophy and strength, crackles, and loss of flexion and extension. It has a score of 0 (no joint damage) to 20 points (maximum joint damage) per joint (elbows, knees and ankles). A gait rating is added to the 120 points (range 0-4 points), the maximum rating on this scale being 124 points
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline balance after treatment and at four weeks
With the Single Leg Stance Test, static postural control and balance will be evaluated. To perform this test, the subject must place both hands on the hips and flex the knee of the non-tested leg, leaving the opposite foot as the only support. The time will be timed (in seconds) from the moment the participant flexes his leg until he places it on the ground again or his hands come off his hips, with a maximum of 60 seconds. This test will be performed with visual support (eyes open) and without it (eyes closed). The longer the time, the better stability. The participants in this study will perform the test twice with each leg, with the best score recorded in the data analysis.
Measured: Screening visit, within the first seven days after treatment and after four weeks follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2024
- Study start6 Apr 2024
- Primary completion3 Jul 2024
- Study completion20 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HemophiliaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- Investigación en Hemofilia y Fisioterapia
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Rubén Cuesta-Barriuso, PhD, Principal investigator, Universidad de Oviedo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06261593
- Sponsor's protocol ID
- Ankle-Blood
- Status last verified
- Mar 2026
- First submitted
- 7 Feb 2024
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of a Physiotherapy Intervention Through Blood Flow Restriction in Improving Muscle Strength in Patients With Hemophilic Ankle Arthropathy: Multicenter Randomized Clinical Study
- ClinicalTrials.gov ID
- NCT06261593
- Acronym / sponsor ID
- Ankle-Blood
- Conditions
- Hemophilia
- Keywords
- Hemophilia, Blood flow restriction, Physiotherapy, Muscular strength, Muscle activation, Range of Motion, Chronic pain, Stability
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- Investigación en Hemofilia y FisioterapiaResearch network
- Study start
- 6 Apr 2024 (actual)
- Primary completion
- 3 Jul 2024 (actual)
- Study completion
- 20 Sep 2024 (actual)
- First posted
- 15 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy.
Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, stability, joint pain, joint status and the perception of quality of life in patients with hemophilic ankle arthropathy.
Study design. Randomized, multicenter, single-blind clinical study. Method. 32 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 4 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (The Single Leg Stance Test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks.
Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Other: Blood flow restrictionThe intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy. The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes. |
| Control group | No intervention | –The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients diagnosed with hemophilia A and B
- People with a medical diagnosis of hemophilic ankle arthropathy
- Patients over 18 years of age
- Paceinets in prophylactic or on-demand treatment regimen with FVIII/FIX concentrates.
- Failure to sign the informed consent document
Key exclusion criteria (3 listed)
- Patients with neurological or cognitive alterations that prevent understanding of the questionnaires
- Amputee patients, epileptics or patients with severe vision problems
- Patients who are receiving physiotherapy treatment at the time of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood flow restrictionThe intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series | Other | Experimental group |
Primary outcome
Change from baseline hemarthrosis after treatment and at 4 weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
A self-registration will be used to evaluate the frequency of bleeding, and thus the safety of the technique. This selfregistration will be given to each patient at the beginning of the study and they must fill in the number of hemarthrosis and their main characteristics: date, origin (traumatic or spontaneous) and location (knee, ankle or elbow). The selfregistration will be delivered to the evaluator in each of the study evaluations (post-treatment and follow-up).
5 secondary outcomes
Change from baseline pressure pain threshold after treatment and at 4 weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline muscle strength after treatment and at 4 weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline electrical activity of the muscles after treatment and at 4 weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline joint status after treatment and at 4 weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
Change from baseline balance after treatment and at four weeks
Time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Hemophilia
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
Active, not recruitingObservational study
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Hemophilia A or B
RecruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hemophilia A
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Hemophilia B
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rubén Cuesta-Barriuso, PhD principal investigator
Universidad de Oviedo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood flow restriction in people with Hemophilia, run by Investigación en Hemofilia y Fisioterapia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline hemarthrosis after treatment and at 4 weeks (time frame: Screening visit, within the first seven days after treatment and after four weeks follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.